Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 3, 2004, Pages 1358-1366

  Acosta, Edward P ^a   Wu, Hulin ^b,l   Hammer, Scott M ^c   Yu, Song ^b   Kuritzkes, Daniel R ^d   Walawander, Ann ^e   Eron, Joseph J ^f   Fichtenbaum, Carl J ^g   Pettinelli, Carla ^h   Neath, Denise ⁱ   Ferguson, Elaine ^h   Saah, Alfred J ^j   Gerber, John G ^k  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Columbia Univ Coll of Phys/Surgs ^*  (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

more..

Author keywords

Antiretroviral therapy; Indinavir; Pharmacokinetics; Ritonavir

Indexed keywords

AMPRENAVIR; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE WEAKNESS; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO REACH MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RITONAVIR; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 7244252991     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200411010-00004     Document Type: Article

References (18)

1. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
2. Acosta EP, Kakuda TN, Brundage RC, et al. Pharmacodynamics of HIV-1 protease inhibitors. Clin Infect Dis. 2000;30(Suppl):S151-S159.
3. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32:194-209.
4. Turner ML, Reed-Walker K, King JR, et al. Simultaneous quantitation of nine antiretroviral agents in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2003;784:331-341.
5. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
6. Voigt E, Wickesberg A, Wasmuth JC, et al. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Medicine. 2002;3:277-282.
7. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003;17:831-840.
8. Lichterfeld M, Nischalke HD, Bergmann F, et al. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med. 2002;3:37-43.
9. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 2002;42:2784-2791.
10. Saah AJ, Winchell GA, Nessly ML, et al. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother. 2001;45:2710-2715.
11. Saquinavir (Fortovase) package insert. Nutley, NJ: Roche; 2000.
12. Fletcher CV, Rhame FS, Beatty CC, et al. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy. 1992;12:429-434.
13. Atazanavir sulfate (Reyataz) package insert. Princeton, NJ: Bristol Myers Squibb Co.; 2003
14. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 trial. J Infect Dis. 2003; 188:635-642.
15. Rockstroh JK, Bergmann F, Wiesel W, et al. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals: German Ritonavir/Indinavir Study Group. AIDS. 2000;14:1181-1185.
16. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother. 2002;46:3907-3916.
17. Ghosn J, Lamotte C, Ait-Mohand H, et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS. 2003;17:209-214.
18. Campo RE, Moreno JN, Suarez G, et al. Efficacy of indinavir-ritonavir- based regimens in HIV-1-infected patients with prior protease inhibitor failures. AIDS. 2003;17:1933-1939.